Consensus-based Recommendation 3.E17 | |
---|---|
Expert consensus | Strength of consensus +++ |
Reference: 60 | |
There are currently no data about the oncological safety of hormone replacement therapy after previous primary treatment of a low-grade ESS. Because the tumor biology of low-grade ESS is highly estrogen-dependent, patients should be dissuaded from starting hormone replacement therapy. |